ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Human Growth Hormone

Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.

Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.

Drug pageHuman Growth Hormone: every studyMany companies study it; this page follows only the 117 they lead. All 217 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 2005117 company-led studies, 5 open or runningNext primary completion: Apr 28, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only340 open or runningphase 4since Sep 13, 2005Feb 1, 2005none ahead
Changchun GeneScience Pharmaceuticalits history only194 open or runningphase 4since Nov 27, 2014Apr 21, 2011Apr 28, 2027phase 4 · NCT07691125
Merck KGaA, Darmstadt, Germanyits history only190 open or runningphase 4since Nov 18, 2005May 13, 2004none ahead
Pfizer180 open or runningphase 4since Feb 5, 2007Sep 9, 2005none ahead
Eli Lillyits history only100 open or runningphase 4since Dec 15, 2005Sep 12, 2005none ahead
LG Chemits history only40 open or runningphase 4since Nov 10, 2016Dec 29, 2005none ahead
Daewoong Pharmaceuticalits history only20 open or runningphase 3since Jan 19, 2016Sep 23, 2011none ahead
Ferring Pharmaceuticalsits history only20 open or runningphase 3since Nov 7, 2005Nov 7, 2005none ahead
Hoffmann-La Rocheits history only20 open or runningphase 4since Dec 4, 2014Mar 11, 2004none ahead
Ipsenits history only20 open or runningphase 4since Aug 24, 2011Oct 5, 2005none ahead

Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2005First studies: 7 phase 3 studiesFirst studyNCT00174291, NCT00174278, NCT00174252 and 4 more
  2. Sep 12, 2005Phase 2 study in Growth Hormone TherapyNCT00174460 · 33 enrolled · Germany
  3. Nov 2, 2006Phase 3 study in Idiopathic Short StatureNCT00396097 · 316 enrolled · United States
  4. Feb 5, 2007Phase 4 study in Brain InjuriesNCT00432263
  5. Oct 24, 2007Phase 4 study in Brain InjuriesNCT00555009 · 10 enrolled · France, Italy, Netherlands and more
  6. Feb 19, 20083 phase 3 studiesNCT00625872, NCT00627523, NCT00630487
  7. Feb 22, 2010Phase 3 study in Growth DisordersNCT01073605 · 208 enrolled · France
  8. Apr 17, 2013Phase 4 study in DwarfismNCT01859949 · 62 enrolled · Japan
  9. Dec 21, 2018Phase 3 study in Dwarfism, PituitaryNCT03831880 · 87 enrolled · United States, Bulgaria, Czechia and more
  10. Jul 28, 2021Named human growth hormoneINNProposed as its International Nonproprietary Name in WHO's List 125
  11. Apr 14, 2026Phase 1 study in HealthyNCT07542886 · 27 enrolled · Belgium

TargetBeta

GHR →read by rule
“Growth hormone receptor agonist”ChEMBL 37, by rule

Other programs on GHR

ProgramCompanyFurthest phaseStudies
lonapegsomatropinruleascendis-pharma-endocrinology-division-a-sphase 36

Studies

All 18 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07542886Healthy · Belgium1CompletedJun 25, 202627
NCT03831880Dwarfism, Pituitary · United States, Bulgaria, Czechia and more3CompletedAug 28, 202087
NCT01859949Dwarfism · Japan4CompletedAug 201562
NCT01073605Growth Disorders · France3CompletedMay 2009208
NCT00630487Dwarfism, Pituitary · Germany3TerminatedOct 20089
NCT00627523Infant, Small for Gestational Age · Belgium, Czech Republic, France and more3CompletedDec 201343
NCT00625872Growth Hormone Therapy · Germany3TerminatedMar 201123
NCT00555009Brain Injuries · France, Italy, Netherlands and more4TerminatedJan 200910
NCT00432263Brain Injuries4Withdrawn0
NCT00396097Idiopathic Short Stature · United States3CompletedAug 2012316
NCT00174460Growth Hormone Therapy · Germany2CompletedMar 200833
NCT00174408Growth Disorders3Completed110
NCT00174291Endocrine System Diseases · France3TerminatedOct 201121
NCT00174278Dwarfism, Pituitary · France3Completed14
NCT00174252Fetal Growth Retardation · France3CompletedApr 200957
NCT00174187Endocrine System Diseases · France3TerminatedSep 201130
NCT00163215Endocrine System Diseases · France3CompletedOct 201146
NCT00163189Dwarfism, Pituitary · France3CompletedDec 201498

How it is read

Names in the registry

  • “somatropin”, 52 entries
  • “Somatropin”, 27 entries
  • “PEG-somatropin”, 13 entries
  • “Saizen®”, 6 entries
  • “Genotropin”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.